Comment
Author: Admin | 2025-04-28
Not necessarily represent the official views of the National Institutes of Health or other funding groups.DisclosureThe authors report no conflicts of interest in this work.References1.Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–2537.2.Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–1436.3.Latus H, Delhaas T, Schranz D, Apitz C. Treatment of pulmonary arterial hypertension in children. Nat Rev Cardiol. 2015;12(4):244–254.4.Vorhies EE, Ivy DD. Drug treatment of pulmonary hypertension in children. Paediatr Drugs. 2014;16(1):43–65.5.Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129(19):1914–1923.6.Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324–334.7.European Medicines Agency Science Medicines Health Assessment report for Revatio. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000638/WC500107804.pdf. Accessed April 14, 2015.8.US Food and Drug Administration. Drug safety communication. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm390876.htm. Accessed April 14, 2015.9.US Food and Drug Administration. Medical, statistical, and clinical pharmacology reviews of pediatric studies conducted under Section 505A and 505B of the Federal Food, drug, and Cosmetic Act, as amended by the FDA Amendments Act of 2012 (FDASIA). Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Devel opmentResources/ucm316937.htm. Accessed April 14, 2015.10.Berger RM,
Add Comment